Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol valerate + cyproterone acetate
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Estradiol valerate + cyproterone acetate is a combination hormone therapy medication that pairs an estrogen (estradiol valerate) with an antiandrogen and progestin (cyproterone acetate). This combination is primarily used for hormone replacement therapy in menopausal women and treatment of androgen-dependent conditions. Estradiol valerate is a prodrug of estradiol that improves oral bioavailability, while cyproterone acetate blocks androgen receptors and has progestogenic effects. The medication is typically administered in a sequential regimen.
- Brand names
- ClimenEstelle-35Estelle35Estelle 35Estelle-35 EDEstelle35 EDEstelle 35 ED
- Other names
- 克龄蒙
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol valerate + cyproterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol valerate + cyproterone acetate.